EFFECTS OF TAMSULOSIN 0.2 MILIGRAM AND TAMSULOSIN 0.4 MILIGRAM ON LOWER URINARY TRACT SYMPTOM SCORE OF USSQ IN PATIENTS WITH INDWELLING DJ STENTS

##plugins.themes.bootstrap3.article.main##

##plugins.themes.bootstrap3.article.sidebar##

PDF
Published 2020-07-20
Dhika Ari Rizki Ferry Safriadi Bambang S Noegroho

Abstract

Objective: To assess the difference in the administration of 0.2 mg and 0.4 mg tamsulosin to the patient's complaint with DJ stent based on USSQ parameters. Material & Methods: This was a prospective study conducted in Hasan Sadikin Hospital Bandung from October to December 2017. A total of 60 patients with indwelling DJ stents randomly divided into 2 groups (n=30). The first group was given tamsulosin 0.2mg daily and the second group was given tamsulosin 0.4 mg daily. LUTSs before and after tamsulosin administration for a week were evaluated in both groups using USSQ. Percentage decreases in USSQ score in both groups were then compared using Mann Whitney Test. Results: In group I, USSQ score means were 31.9 (20.0-40.0; SD 31.9) before tamsulosin 0.2 mg administration and 26.1 (15.0-35.0; SD 5.6) after tamsulosin 0.2 mg administration. Comparison test before and after tamsulosin 0.2 mg administration showed significant decrease in USSQ score.  In group II, USSQ score means were 38.9 (31.0-44.0; SD 2.9) before tamsulosin 0.4 mg administration and 16.7 (13.0-21.0; SD 1.8) after tamsulosin 0.4 mg administration. Comparison test before and after tamsulosin 0.4 mg administration showed significant decrease in USSQ score. The percentage decreases in USSQ score were 18.7% in group I and 56.9% in group II. Different test score before and after treatment for both groups showed p-value<0.05. Scoring results after treatment showed the effectiveness of tamsulosin 0.4 mg was better than tamsulosin 0.2 mg. Conclusion: LUTS is the most common stent-associated symptom (SAS) in patients with indwelling DJ stent. Independent administration of tamsulosin 0.2 mg and 0.4 mg significantly alleviated SAS. Tamsulosin 0.4 mg had better effectiveness in alleviating SAS compared to tamsulosin 0.2 mg.


##plugins.themes.bootstrap3.article.details##

Keywords

stent-associated symptom, tamsulosin, USSQ

References

Miyaoka R, Monga M. Ureteral stent discomfort: Etiology and management. Indian journal of urology: IJU: journal of the Urological Society of India. 2009; 25(4): 455-60.

Irani J, Siquier J, Pires C, Lefebvre O, Dore B, Aubert J. Symptom characteristics and the development of tolerance with time in patients with indwelling double-pigtail ureteric stents. BJU international. 1999; 84(3): 276-9.

Joshi HB, Stainthorpe A, MacDonagh RP, Keeley FX, Jr., Timoney AG, Barry MJ. Indwelling ureteral stents: evaluation of symptoms, quality of life and utility. The Journal of urology. 2003; 169(3): 1065-9.

Joshi HB, News N, Stainthorpe A, MacDonagh RP, Keeley FX, Jr., Timoney AG. Ureteral stent symptom questionnaire: development and validation of a multidimensional quality of life measure. The Journal of urology. 2003; 169(3): 1060-4.

Park HJ, Won JE, Sorsaburu S, Rivera PD, Lee SW. Urinary Tract Symptoms (LUTS) Secondary to Benign Prostatic Hyperplasia (BPH) and LUTS/BPH with Erectile Dysfunction in Asian Men: A Systematic Review Focusing on Tadalafil. The world journal of men's health. 2013; 31(3): 193-207.

Kim JJ, Han DH, Sung HH, Choo SH, Lee SW. Efficacy and tolerability of tamsulosin 0.4 mg in Asian patients with lower urinary tract symptoms secondary to benign prostatic hyperplasia refractory to tamsulosin 0.2 mg: a randomized placebo controlled trial. International Journal of urology: official journal of the Japanese Urological Association. 2014; 21(7): 677-82.

Section
Articles
Copyright Information
Department of Urology, Faculty of Medicine/Airlangga University